Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 951 | 967 | 1087 | 788 | 1312 | 2418 |
Fund Return | -4.91% | -3.33% | 8.74% | -7.63% | 5.59% | 9.23% |
Place in category | 521 | 528 | 502 | 456 | 400 | 252 |
% in Category | 96 | 98 | 92 | 89 | 87 | 65 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Eventide Gilead I | 2.49B | -4.60 | -6.70 | 10.33 | ||
Eventide Healthcare & Life ScienceI | 1.2B | -8.19 | -9.33 | 10.90 | ||
Eventide Gilead N | 438.86M | -4.67 | -6.89 | 10.11 | ||
Eventide Gilead A | 324.57M | -4.66 | -6.92 | 10.07 | ||
Eventide Healthcare & Life ScienceA | 126M | -8.30 | -9.55 | 10.63 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
T. Rowe Price Mid-Cap Growth I | 12.43B | 2.15 | 0.66 | - | ||
T. Rowe Price Mid-Cap Growth | 12.22B | 2.11 | 0.53 | 10.72 | ||
Principal MidCap Institutional | 11.96B | 3.94 | 4.54 | 12.12 | ||
Vanguard Mid-Cap Growth Index Admir | 11.29B | 2.05 | 0.43 | 10.29 | ||
T. Rowe Price New Horizons I | 10.77B | -3.06 | -8.15 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Xometry Inc Ordinary Shares - Class A | - | 4.99 | - | - | |
Trane Technologies | IE00BK9ZQ967 | 3.91 | 327.18 | +0.67% | |
Old Dominion Freight Line | US6795801009 | 3.76 | 175.25 | +1.28% | |
IDEXX Labs | US45168D1046 | 3.22 | 496.95 | -0.56% | |
CrowdStrike Holdings | US22788C1053 | 3.17 | 313.67 | -0.71% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Sell |
Technical Indicators | Strong Sell | Strong Sell | Neutral |
Summary | Strong Sell | Strong Sell | Neutral |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review